Drug Trial Radar · NCT05364073
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Actual
Start
Jun 30, 2022
Primary completion
Jun 3, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- ArriVent BioPharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Lung Cancer
- HER2 Exon 20 Mutations
- EGFR Exon 20 Mutations
- EGFR Uncommon Mutations, Including G719X and S768I
Interventions
FurmonertinibDrug
Furmonertinib tablet
FurmonertinibDrug
Furmonertinib tablet
FurmonertinibDrug
Furmonertinib tablet
FurmonertinibDrug
Furmonertinib tablet
FurmonertinibDrug
Furmonertinib tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of FurmonertinibTime frame: Up to 36 months after first dose
- Stage 2: Overall Response Rate (ORR)Time frame: Up to 36 months after first dose
Locations
42 sites in 11 countries. Site status is shown where the registry gives one.
ArriVent Investigative Site
Prescott, Arizona
ArriVent Investigative Site
Sacramento, California
ArriVent Investigative Site
Whittier, California
ArriVent Investigative Site
Celebration, Florida
ArriVent Investigative Site
Detroit, Michigan
ArriVent Investigative Site
Houston, Texas
ArriVent Investigative Site
Fairfax, Virginia
ArriVent Investigative Site
Blacktown, New South Wales, Australia
ArriVent Investigative Site
St Leonards, New South Wales, Australia
ArriVent Investigative Site
Heidelberg, Victoria, Australia
Arrivent Investigative Site
Edmonton, Canada
Arrivent Investigative Site
Toronto, Canada
Allist Investigative Site
Hefei, Anhui, China
Allist Investigative Site
Beijing, Beijing Municipality, China
Allist Investigative Site
Chaoyang, Beijing Municipality, China
Allist Investigative Site
Chongqing, Chongqing Municipality, China
Allist Investigative Site
Harbin, Heilongjiang, China
Allist Investigative Site
Zhengzhou, Henan, China
Allist Investigative Site
Zhengzhou, Henan, China
Allist Investigative Site
Wuhan, Hubei, China
Allist Investigative Site
Xuzhou, Jiangsu, China
Allist Investigative Site
Nanchang, Jianxi, China
Allist Investigative Site
Changchun, Jilin, China
Allist Investigative Site
Jinan, Shandong, China
Allist Investigative Site
Jinan, Shandong, China
Allist Investigative Site
Taiyuan, Shanxi, China
ArriVent Investigative Site
Lyon, France
Arrivent Investigative Site
Toulouse, France
Arrivent Investigative Site
Villejuif, France
ArriVent Investigative Site
Medolla, Italy
ArriVent Investigative Site
Chiba, Chiba, Japan
Arrivent Investigative Site
Ōsaka-sayama, Osaka, Japan
Arrivent Investigative Site
Chūō, Tokyo, Japan
Arrivent Investigative Site
Koto-Ku, Tokyo, Japan
Arrivent Investigative Site
Amsterdam, North Holland, Netherlands
Arrivent Investigative Site
Gwangju, South Korea
Arrivent Investigative Site
Seoul, South Korea
ArriVent Investigative Site
Barcelona, Spain
ArriVent Investigative Site
Madrid, Spain
ArriVent Investigative Site
Madrid, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.